Go To Global Site
Welcome to UCB in the United States



UCB Announces New Data from its Epilepsy Portfolio Presented on the American Academy of Neurology Virtual Platform

Six poster presentations highlight clinical data on NAYZILAM® (midazolam) nasal spray CIV and BRIVIACT® (brivaracetam) CV in addition to epilepsy-related health economics outcomes research

Atlanta, Ga., June 24, 2020: UCB today announced six posters selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting, available online via the 2020 AAN Science Highlights virtual platform, which replaced the in-person event previously cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.



Press Release: UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.

• NAYZILAM will be available in retail pharmacies on December 2, 2019
• Copay support and a patient assistance program will be provided by UCB for eligible NAYZILAM patients*